Bertram L. Kasiske
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bertram L. Kasiske has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Ajay K. Israni
University of Texas Medical Branch, Galveston, Texas
10 shared publications - Jon J. Snyder
Hennepin Healthcare Research Institute, Minneapolis, Minnesota
8 shared publications - Cory R. Schaffhausen
Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA; Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, USA
4 shared publications - Allyson Hart
Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota
3 shared publications - Andrew Wey
Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA
3 shared publications - Arthur J. Matas
Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, USA
3 shared publications
Latest Publications
- Top Cited Papers
- 1 May 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (5) , 705-713
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy. The KDIGO CKD Guideline Work Group defined the scope of the guideline and determined topics for systematic review. An independent Evidence Review Team systematically reviewed the evidence and graded the certainty of evidence for each of the review topics. Latest searches of the English-language literature were done in July 2023. Final modification of the guideline was informed by a public review process during summer of 2023 involving registered stakeholders. The full guideline included 28 recommendations and 141 practice points. This synopsis focuses on the recommendations that have the greatest evidence. Practice points reflect the expert opinion of the group where evidence is not that strong. Recommendations include greater emphasis on cystatin C for assessment of glomerular filtration rate, point-of-care testing in remote areas, a shift to an individualized risk-based approach to predict kidney failure, sodium-glucose cotransporter-2 inhibitors for some patients with CKD with and without diabetes, and statin use for adults older than 50 years and CKD. Together the recommendations and practice points provide guidance for how to evaluate and manage persons with CKD.
- 1 May 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (5) , 705-713
Top Cited PapersEvaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy. The KDIGO CKD Guideline Work Group defined the scope of the guideline and determined topics for systematic review. An independent Evidence Review Team systematically reviewed the evidence and graded the certainty of evidence for each of the review topics. Latest searches of the English-language literature were done in July 2023. Final modification of the guideline was informed by a public review process during summer of 2023 involving registered stakeholders. The full guideline included 28 recommendations and 141 practice points. This synopsis focuses on the recommendations that have the greatest evidence. Practice points reflect the expert opinion of the group where evidence is not that strong. Recommendations include greater emphasis on cystatin C for assessment of glomerular filtration rate, point-of-care testing in remote areas, a shift to an individualized risk-based approach to predict kidney failure, sodium-glucose cotransporter-2 inhibitors for some patients with CKD with and without diabetes, and statin use for adults older than 50 years and CKD. Together the recommendations and practice points provide guidance for how to evaluate and manage persons with CKD.
- Open Access
- 7 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 72-87
Subthreshold rejection activity in many kidney transplants currently classified as having no rejection
- 7 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 72-87
Open AccessSubthreshold rejection activity in many kidney transplants currently classified as having no rejection
- Open Access
- 21 March 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (7) , 875-890
Stakeholders’ perspectives on transplant metrics: the 2022 Scientific Registry of Transplant Recipients’ consensus conference
- 21 March 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (7) , 875-890
Open AccessStakeholders’ perspectives on transplant metrics: the 2022 Scientific Registry of Transplant Recipients’ consensus conference
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2616-2626
Transplant program evaluations in the middle of the COVID-19 pandemic
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2616-2626
Open AccessTransplant program evaluations in the middle of the COVID-19 pandemic
- 13 October 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (12) , e14817
The need for integrated clinical and administrative data models for risk adjustment in assessment of the cost transplant care
Introduction: Value‐based purchasing requires accurate techniques to appropriately measure both outcomes and cost with robust adjustment for differences in severity of illness. Traditional methods to adjust cost estimates have exclusively used administrative data derived from billing claims to identify comorbidity and complications. Transplantation uniquely has accurate national clinical registry data that can be used to supplement administrative data.Methods: Administrative claims from the Vizient, Inc, Clinical Data Base (CDB) were linked with clinical records from the Scientific Registry for Transplant Recipients for 76 liver and 109 kidney transplant programs. Using either or both datasets, we fitted a regression model to the total direct cost of care for 16,649 kidney and 6058 liver transplants.Results: The proportion of variation explained by these risk‐adjustment models increased significantly when combined administrative and clinical data were used for kidney (administrative only R2= .069, clinical only R2= .047, combined R2= .14, p < .0001) and liver (administrative only R2= .28, clinical only R2= .25, combined R2= .33, p < .0001).Conclusion: Incorporating accurate clinical data into risk‐adjustment methodologies can improve risk adjustment methodologies; however, as majority of variation in cost remains unexplained by these risk‐adjustment models further work is needed to accuracy assess transplant value.
- 13 October 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (12) , e14817
The need for integrated clinical and administrative data models for risk adjustment in assessment of the cost transplant care
Introduction: Value‐based purchasing requires accurate techniques to appropriately measure both outcomes and cost with robust adjustment for differences in severity of illness. Traditional methods to adjust cost estimates have exclusively used administrative data derived from billing claims to identify comorbidity and complications. Transplantation uniquely has accurate national clinical registry data that can be used to supplement administrative data.Methods: Administrative claims from the Vizient, Inc, Clinical Data Base (CDB) were linked with clinical records from the Scientific Registry for Transplant Recipients for 76 liver and 109 kidney transplant programs. Using either or both datasets, we fitted a regression model to the total direct cost of care for 16,649 kidney and 6058 liver transplants.Results: The proportion of variation explained by these risk‐adjustment models increased significantly when combined administrative and clinical data were used for kidney (administrative only R2= .069, clinical only R2= .047, combined R2= .14, p < .0001) and liver (administrative only R2= .28, clinical only R2= .25, combined R2= .33, p < .0001).Conclusion: Incorporating accurate clinical data into risk‐adjustment methodologies can improve risk adjustment methodologies; however, as majority of variation in cost remains unexplained by these risk‐adjustment models further work is needed to accuracy assess transplant value.
- 6 June 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (7) , e14716
Toward continuous improvement of Scientific Registry of Transplant Recipients performance reporting: Advances following 2012 consensus conference and future consensus building for 2022 consensus conference
The Scientific Registry of Transplant Recipients (SRTR) held a consensus conference in 2012 that examined methods used by SRTR for constructing performance metrics and made recommendations on how to improve program‐specific reports. That consensus conference provided 25 recommendations categorized as follows: statistical methods, risk adjustment, and outcomes and data. During the subsequent decade, SRTR has implemented most of these recommendations; these are described in this article along with plans for another consensus conference in 2022. With the present article, SRTR aims to create transparency in the field of transplant metrics and guide discussion in the planning of the next consensus conference in 2022. The new conference will revisit the previous topics and have a broader focus to improve the metrics and information that SRTR provides. Readers can provide feedback on topics to be discussed at the next consensus conference as early as possible, by emailing srtr@srtr.org with the subject line “Task 5 Public Comment.”
- 6 June 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (7) , e14716
Toward continuous improvement of Scientific Registry of Transplant Recipients performance reporting: Advances following 2012 consensus conference and future consensus building for 2022 consensus conference
The Scientific Registry of Transplant Recipients (SRTR) held a consensus conference in 2012 that examined methods used by SRTR for constructing performance metrics and made recommendations on how to improve program‐specific reports. That consensus conference provided 25 recommendations categorized as follows: statistical methods, risk adjustment, and outcomes and data. During the subsequent decade, SRTR has implemented most of these recommendations; these are described in this article along with plans for another consensus conference in 2022. With the present article, SRTR aims to create transparency in the field of transplant metrics and guide discussion in the planning of the next consensus conference in 2022. The new conference will revisit the previous topics and have a broader focus to improve the metrics and information that SRTR provides. Readers can provide feedback on topics to be discussed at the next consensus conference as early as possible, by emailing srtr@srtr.org with the subject line “Task 5 Public Comment.”
- Open Access
- 5 May 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (8) , 2006-2015
Cancer risk in living kidney donors
- 5 May 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (8) , 2006-2015
Open AccessCancer risk in living kidney donors
- 14 March 2022
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 80 (5) , 683-685
Associations of Lack of Insurance and Other Sociodemographic Traits With Follow-up After Living Kidney Donation
- 14 March 2022
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 80 (5) , 683-685
Associations of Lack of Insurance and Other Sociodemographic Traits With Follow-up After Living Kidney Donation
- Open Access
- 11 February 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (8) , 1517-1519
Deconstructing Silos of Knowledge Around Lung Transplantation to Support Patients: A Patient-specific Search of Scientific Registry of Transplant Recipients Data
- 11 February 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (8) , 1517-1519
Open AccessDeconstructing Silos of Knowledge Around Lung Transplantation to Support Patients: A Patient-specific Search of Scientific Registry of Transplant Recipients Data
- 5 September 2021
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 28 (3) , 363-375
The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End‐Stage Liver Disease Scores and Exception Statuses
Acuity circles (AC), the new liver allocation system, was implemented on February 4, 2020. Difference‐in‐differences analyses estimated the effect of AC on adjusted deceased donor transplant and offer rates across Pediatric End‐Stage Liver Disease (PELD) and Model for End‐Stage Liver Disease (MELD) categories and types of exception statuses. The offer rates were the number of first offers, top 5 offers, and top 10 offers on the match run per person‐year. Each analysis adjusted for candidate characteristics and only used active candidate time on the waiting list. The before‐AC period was February 4, 2019, to February 3, 2020, and the after‐AC period was February 4, 2020, to February 3, 2021. Candidates with PELD/MELD scores 29 to 32 and PELD/MELD scores 33 to 36 had higher transplant rates than candidates with PELD/MELD scores 15 to 28 after AC compared with before AC (transplant rate ratios: PELD/MELD scores 29‐32, 2.343.324.71; PELD/MELD scores 33‐36, 1.702.513.71). Candidates with PELD/MELD scores 29 or higher had higher offer rates than candidates with PELD/MELD scores 15 to 28, and candidates with PELD/MELD scores 29 to 32 had the largest difference (offer rate ratios [ORR]: first offers, 2.773.955.63; top 5 offers, 3.904.394.95; top 10 offers, 4.855.305.80). Candidates with exceptions had lower offer rates than candidates without exceptions for offers in the top 5 (ORR: hepatocellular carcinoma [HCC], 0.680.770.88; non‐HCC, 0.730.810.89) and top 10 (ORR: HCC, 0.590.650.71; non‐HCC, 0.690.750.81). Recipients with PELD/MELD scores 15 to 28 and an HCC exception received a larger proportion of donation after circulatory death (DCD) donors after AC than before AC, although the differences in the liver donor risk index were comparatively small. Thus, candidates with PELD/MELD scores 29 to 34 and no exceptions had better access to transplant after AC, and donor quality did not notably change beyond the proportion of DCD donors.
- 5 September 2021
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 28 (3) , 363-375
The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End‐Stage Liver Disease Scores and Exception Statuses
Acuity circles (AC), the new liver allocation system, was implemented on February 4, 2020. Difference‐in‐differences analyses estimated the effect of AC on adjusted deceased donor transplant and offer rates across Pediatric End‐Stage Liver Disease (PELD) and Model for End‐Stage Liver Disease (MELD) categories and types of exception statuses. The offer rates were the number of first offers, top 5 offers, and top 10 offers on the match run per person‐year. Each analysis adjusted for candidate characteristics and only used active candidate time on the waiting list. The before‐AC period was February 4, 2019, to February 3, 2020, and the after‐AC period was February 4, 2020, to February 3, 2021. Candidates with PELD/MELD scores 29 to 32 and PELD/MELD scores 33 to 36 had higher transplant rates than candidates with PELD/MELD scores 15 to 28 after AC compared with before AC (transplant rate ratios: PELD/MELD scores 29‐32, 2.343.324.71; PELD/MELD scores 33‐36, 1.702.513.71). Candidates with PELD/MELD scores 29 or higher had higher offer rates than candidates with PELD/MELD scores 15 to 28, and candidates with PELD/MELD scores 29 to 32 had the largest difference (offer rate ratios [ORR]: first offers, 2.773.955.63; top 5 offers, 3.904.394.95; top 10 offers, 4.855.305.80). Candidates with exceptions had lower offer rates than candidates without exceptions for offers in the top 5 (ORR: hepatocellular carcinoma [HCC], 0.680.770.88; non‐HCC, 0.730.810.89) and top 10 (ORR: HCC, 0.590.650.71; non‐HCC, 0.690.750.81). Recipients with PELD/MELD scores 15 to 28 and an HCC exception received a larger proportion of donation after circulatory death (DCD) donors after AC than before AC, although the differences in the liver donor risk index were comparatively small. Thus, candidates with PELD/MELD scores 29 to 34 and no exceptions had better access to transplant after AC, and donor quality did not notably change beyond the proportion of DCD donors.